Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
- 12 November 2015
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 373 (20), 1905-1915
- https://doi.org/10.1056/nejmoa1509038
Abstract
In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascular scaffolds have been developed to attempt to improve long-term outcomes. In this large, multicenter, randomized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to receive an everolimus-eluting bioresorbable vascular (Absorb) scaffold (1322 patients) or an everolimus-eluting cobalt–chromium (Xience) stent (686 patients). The primary end point, which was tested for both noninferiority (margin, 4.5 percentage points for the risk difference) and superiority, was target-lesion failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization) at 1 year. Target-lesion failure at 1 year occurred in 7.8% of patients in the Absorb group and in 6.1% of patients in the Xience group (difference, 1.7 percentage points; 95% confidence interval, −0.5 to 3.9; P=0.007 for noninferiority and P=0.16 for superiority). There was no significant difference between the Absorb group and the Xience group in rates of cardiac death (0.6% and 0.1%, respectively; P=0.29), target-vessel myocardial infarction (6.0% and 4.6%, respectively; P=0.18), or ischemia-driven target-lesion revascularization (3.0% and 2.5%, respectively; P=0.50). Device thrombosis within 1 year occurred in 1.5% of patients in the Absorb group and in 0.7% of patients in the Xience group (P=0.13). In this large-scale, randomized trial, treatment of noncomplex obstructive coronary artery disease with an everolimus-eluting bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt–chromium stent, was within the prespecified margin for noninferiority with respect to target-lesion failure at 1 year. (Funded by Abbott Vascular; ABSORB III ClinicalTrials.gov number, NCT01751906.)Keywords
This publication has 29 references indexed in Scilit:
- Long-Term Safety of Drug-Eluting and Bare-Metal StentsJournal of the American College of Cardiology, 2015
- Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element StentsJACC: Cardiovascular Interventions, 2015
- Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in HumansCirculation, 2014
- 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting StentsJACC: Cardiovascular Interventions, 2013
- Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary DiseaseThe New England Journal of Medicine, 2012
- Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary StentsCirculation, 2012
- Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass SurgeryThe New England Journal of Medicine, 2011
- Safety and Efficacy of Drug-Eluting and Bare Metal StentsCirculation, 2009
- Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic RiskJournal of the American College of Cardiology, 2006
- Chest pain after coronary artery stent implantationThe American Journal of Cardiology, 2002